11
Jun 2014
Share This
0 Comments
ISSCR Screen Capture

What’s the ‘real deal’ on stem cells?

Posted by

The day before 3,600 scientists, clinicians, educators and industry professionals from around the world gather in Vancouver next week for the International Society of Stem Cell Researchers’ summit, the public will get a chance to hear about the ‘real deal’ on stem cells.

Moderated by the Vancouver Sun’s Pamela Fayerman, the Tuesday, June 17th symposium focuses on why stem cells, which have been hailed for the past two decades as having the potential to fight so many diseases, have — with some notable exceptions — been slow to deliver.

The panel that includes Prof. Timothy Caulfield, author of The Cure for Everything and member of our Foundation’s Science Leadership Council, and stem cell transplant recipient Jennifer Molson will tackle the question: Why is it taking so long to make these promised therapies a reality? Industry investment expert Gregory Bonfiglio of Proteus Venture Partners and University of British Columbia stem cell researcher Dr. Kelly McNagny will also share their views.

It’s an important question. The translation of stem cell research discoveries into stem cell therapies takes a long time. It includes securing funding, getting regulatory approvals and conducting rigorous — and hugely expensive — clinical trials. In the meantime, unregulated clinics are popping up around the planet, offering “miracle” stem cell cures that have not been proven safe or effective.

The symposium, sponsored by the Stem Cell Network and the Centre for Commercialization of Regenerative Medicine, will be held in the OmniMax Theatre at Science World at TELUS World of Science. For more information, click here.

Leave a Reply

Your email address will not be published. Required fields are marked *

If you are a human, do not fill out this field